137778-20-2

Usage

Uses

Used in Pharmaceutical Industry:
3-Bromo-2-Methylpyridine-6-carboxylic acid is used as a building block for the synthesis of various pharmaceutical compounds due to its reactivity and versatility. Its unique functional groups allow for the creation of new molecules with potential therapeutic properties.
Used in Organic Synthesis:
3-Bromo-2-Methylpyridine-6-carboxylic acid is used as a key intermediate in organic synthesis for the development of novel organic compounds. Its reactivity and the presence of bromine make it a valuable component in the synthesis of complex organic molecules with potential applications in various fields.
While the specific applications of 3-Bromo-2-Methylpyridine-6-carboxylic acid are not explicitly mentioned in the provided materials, its chemical properties and structural features suggest that it could be utilized in the development of new pharmaceuticals and organic compounds. Its potential lies in its ability to serve as a versatile building block in complex synthesis processes, contributing to the advancement of chemical research and product development in relevant industries.

Upstream product

• 137778-18-8 5-bromo-6-methyl-pyridine-2-carbaldehyde 
• 1173897-86-3 5-bromo-6-methylpyridine-2-carbonitrile 
• 1122090-67-8 3-bromo-2-methyl-6-vinylpyridine 
• 137778-11-1 (5-bromo-6-methylpyridin-2-yl)methanol 
• 87180-69-6 3‐bromo‐2,6‐dimethylpyridine‐1‐oxide 

Relevant academic research and scientific papers

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

Process for preparing 2-alkyl-3-halo-6-nitrilpyridine and its carboxylic acid and ester derivatives

A process for preparing 2-alkyl-3-halo-6-nitrilpyridine and its carboxylic acid and ester derivatives by reacting 2-alkyl-3-halo-pyridine N-oxide with dimethyl sulfate, followed by reacting the adduct with alkaline cyanide to obtain the target molecule is disclosed. Further treatment of the nitrile with base to obtain the corresponding acid, and esterification are described as well. The process was scaled up to multi-kilogram level that provided satisfactory output.

THE REARRANGEMENT OF 3-CHLORO- AND 3-BROMO-2,6-DIMETHYLPYRIDINE N-OXIDE UNDER THE ACTION OF ACETIC ANHYDRIDE

The rearrangement of 3-chloro and 3-bromo-2,6-dimethylpyridine N oxides under the influence of acetic anhydride was investigated.The rearrangement products: 3-halo-2-methyyl-6-pyridylmethanol and 3-halo-2,6-dimethyl-5-hydroxypyridine acetates were separated and hydrolyzed to corresponding alcohols. 3-Halo-2-methyl-6-pyridylmethanols were oxidized to aldehydes and carboxylic acids.Structures of pyridylmethanols and hydroxy derivatives have been determined by IR spectra analysis or by chemical methods.